Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | MST1R | Q04912 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL8138709 | 0.89 | MAPK8 (0.40) | HTR2AMAPK8MAPK9MAPK10NTRK1 | |
| Fumaric Acid SCHEMBL8138713 | 0.89 | MAPK8 (0.40) | HTR2AMAPK8MAPK9MAPK10NTRK1 | |
| SCHEMBL905871 | 0.84 | HTR2A (0.43) | HTR2AMAPK8MAPK9MAPK10PNMT | |
| SCHEMBL16881243 | 0.83 | MAPK8 (0.49) | MAPK8MAPK9MAPK10KDM4C | |
| SCHEMBL5989789 | 0.82 | HTR1A (0.43) | HTR2AHTR2CSLC6A2 | |
| SCHEMBL905832 | 0.80 | HTR2A (0.46) | HTR2AHTR2C | |
| SCHEMBL15898846 | 0.80 | GABRA1 (0.48) | MAPK8MAPK9MAPK10KDM4C | |
| SCHEMBL13106420 | 0.80 | MAPK8 (0.56) | MAPK8MAPK9MAPK10PIM1KDM4C | |
| SCHEMBL5989088 | 0.78 | KDM4E (0.43) | HTR2AHTR2CSLC6A2SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL905753 | 0.76 | MAPK8 (0.56) | MAPK8MAPK9MAPK10PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000012482-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| CN-1780612-B | Treatment of incontinence with 5HT2C agonists. | PFIZER | 2010-12-01 | — | — | CN | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| CN-1780612-A | Treatment of incontinence with 5HT2C agonists. | PFIZER (US) | 2006-05-31 | — | — | CN | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| WO-2000012482-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885MAPK8 3756/4885MAPK9 4392/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885MAPK8 3756/4885MAPK9 4392/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885MAPK8 3756/4885MAPK9 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.